Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a ...

The FDA has declared the end of the two-year shortages of Eli Lilly's Mounjaro and Zepbound — used to treat diabetes and weight loss, respectively — and has reaffirmed its decision to halt the ...

The FDA removed Eli Lilly’s LLY tirzepatide injection products from the drug shortage list after determining that Lilly’s ...

Lilly markets tirzepatide as Zepbound for obesity and as Mounjaro for type II diabetes. Though demand for the two drugs remains massive, Mounjaro and Zepbound’s sales were hurt due to inventory ...

Tirzepatide, the key ingredient in Zepbound and Mounjaro, stimulates the GIP and GLP-1 receptors. Learn more about how to get GLP-1 medications like Zepbound and Mounjaro from vetted and trusted ...

Details about its clinical results are still emerging but ZepBound looks like another tool to manage obesity and related health conditions. All of these medications-Mounjaro, Wegovy, Ozempic and ...

Wegovy and Mounjaro have helped millions of Americans lose weight and better manage their type 2 diabetes. Now, new research suggests Eli Lilly’s weight loss drug Zepbound (tirzepetide ...

Lilly markets tirzepatide as Zepbound for obesity and as Mounjaro for type II diabetes. Despite a short time on the market, Mounjaro and Zepbound have become key top-line drivers for Lilly in 2024 ...

Lilly said Thursday it will expand a Kenosha County, Wisconsin, factory it bought early this year, and the investment will ...